Cointime

Synosia Therapeutics

company

About

Synosia Therapeutics develops and commercializes products for unmet medical needs in psychiatry and neurology.

  • 1 - 10

Highlights

Total Funding Amount
$91.50M
Funding Rounds
3
Investors
2

Details

Last Funding Type
Series C
Last Funding Money Raised
$30M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2006
Number Of Employee
1 - 10
Operating Status
Active

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$91.50M
Synosia Therapeutics has raised a total of $91.50M in funding over 2 rounds. Their latest funding was raised on Oct 12, 2010 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 12, 2010 Series C $30M 2 UCB — Detail
Jan 1, 2009 Series B $29M 1 — — Detail
Jan 5, 2007 Series Unknown $32.50M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Synosia Therapeutics is funded by 2 investors. UCB and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
UCB Yes Series C
Versant Ventures — Series C
Cointime
Chủ Đề
Công Ty